Paolo Morandi
Overview
Explore the profile of Paolo Morandi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonanno L, Calvetti L, Dal Maso A, Pavan A, Bao L, De Nuzzo M, et al.
Front Immunol
. 2024 Feb;
15:1353889.
PMID: 38322260
Background: Recent clinical trials demonstrated longer survival in extended small cell lung cancer (SCLC) patients treated with immunotherapy in addition to chemotherapy. However, the magnitude of benefit is modest and...
2.
Corbella S, Morandi P, Alberti A, Morandi B, Francetti L
Clin Oral Implants Res
. 2022 Jun;
33(8):834-843.
PMID: 35726403
Objective: The present retrospective study investigated the effect of chronic intake of proton pump inhibitors, selective serotonin uptake inhibitors, anti-inflammatory, and antihypertensive drugs on the survival of dental implants and...
3.
Gion M, Cardinali G, Guzzinati S, Morandi P, Trevisiol C, Fabricio A, et al.
Risk Manag Healthc Policy
. 2022 May;
15:1087-1100.
PMID: 35615584
Purpose: Clinical practice guidelines (CPGs) recommend against intensive follow-up in asymptomatic women with breast cancer (BC). The present study assessed the adherence to CPGs of diagnostic tests ordering during BC...
4.
Pasello G, Lorenzi M, Calvetti L, Oliani C, Pavan A, Favaretto A, et al.
Oncologist
. 2022 Apr;
27(6):e484-e493.
PMID: 35429394
Background: Real-world (RW) evidence on nivolumab in pretreated patients with non-small cell lung cancer (NSCLC) by matching data from administrative health flows (AHFs) and clinical records (CRs) may close the...
5.
Guarneri V, Bassan F, Zagonel V, Milella M, Zaninelli M, Cattelan A, et al.
Eur J Cancer
. 2021 Mar;
147:120-127.
PMID: 33647547
Introduction: Coronavirus disease 2019 (COVID-19) pandemic started in Italy with clusters identified in Northern Italy. The Veneto Oncology Network (Rete Oncologica Veneta) licenced dedicated guidelines to ensure proper care minimising...
6.
Alberti A, Morandi P, Zotti B, Tironi F, Francetti L, Taschieri S, et al.
Dent J (Basel)
. 2020 Jul;
8(3).
PMID: 32635449
Diabetes is an important modifying factor of periodontitis, but its association with peri-implant diseases has not been fully explored and the existing literature reports controversial results. The aim of this...
7.
Dieci M, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, et al.
Oncologist
. 2019 Jun;
24(11):1424-1431.
PMID: 31152079
Background: The ROXANE Italian prospective study evaluated the impact of the 21-gene Recurrence Score (RS) results on adjuvant treatment decision for patients with early breast cancer. Materials And Methods: Nine...
8.
Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes A, Bisagni G, et al.
Eur J Cancer
. 2018 Nov;
105:61-70.
PMID: 30396014
Background: Subcutaneous trastuzumab (H SC) is a valuable alternative to the intravenous formulation. This study assessed H SC safety and tolerability in human epidermal growth factor receptor 2 (HER2)+ early/locally...
9.
Morandi P, Hak S, Magenes G
Data Brief
. 2018 Mar;
16:886-904.
PMID: 29541677
This article contains information related to a recent study "Performance-based interpretation of in-plane cyclic tests on RC frames with strong masonry infills" (Morandi et al., 2017 [1]). Motivated by the...
10.
Gianni L, Pienkowski T, Im Y, Tseng L, Liu M, Lluch A, et al.
Lancet Oncol
. 2016 May;
17(6):791-800.
PMID: 27179402
Background: In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel...